|
|
|
|
Oral Contraceptives Effective for Endometriosis-Related Dysmenorrhea
NEW YORK (Reuters Health) Nov 28 - Treatment with a low-dose oral contraceptive pill (OCP) can reduce dysmenorrhea and non-menstrual pain associated with endometriosis, according to a report in the November issue of Fertility and...
|
|
|
Oral Contraceptives Effective for Endometriosis-Related Dysmenorrhea
_ Oral Contraceptives Effective for Endometriosis-Related Dysmenorrhea.
|
|
|
Oral contraceptives effective for endometriosis-related dysmenorrhea
NEW YORK (Reuters Health) - Treatment with a low-dose oral contraceptive pill (OCP) can reduce dysmenorrhea and non-menstrual pain associated with endometriosis, according to a report in the November issue of Fertility and Sterility.
|
|
|
Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis
About MDLinx| Contact | Advertise with MDLinx | Site Map | Privacy Policy | Terms of Use | Sign Up For Newsletters | Recommend this Site English| Espaol | F Low-dose oral contraceptive pill for dysmenorrhea associated with...
|
|
|
Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
The invention relates to compositions and methods for a one-step synthetic technique for making cationic steroid or cationic drug molecules for use as delivery vehicles.The invention further relates to methods for using cationic steroid...
|
|
|
Malondialdehyde, nitric oxide and adrenomedullin levels in patients with primary dysmenorrhea
Dikensoy E et al.- The results of this study showed that the serum levels of MDA, NO, and AM increase in subjects with primary dysmenorrhea, suggesting the possibility that lipid peroxidation and oxidative stress play a significant...
|
|
|
FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive
Duramed to Launch First Lower-Dose, Extended-Cycle Oral Contraceptive for the Prevention of Pregnancy MONTVALE, N.J., Oct.27 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that the U.S. Food and Drug...
|
|
|
Columbia Laboratories presents findings from Phase II dysmenorrhea study
Approximately 70 women with a history of moderate-to-severe dysmenorrhea participated in this first documented attempt to show prevention of uterine cramping and pain.This double-blind, placebo-controlled clinical trial used a cross...
|
|
|
Warming and nonirritating lubricant compositions and method of comparing irritation
Pharmaceutical Patents Title: United States Patent: 7,417,013 Issued: August 26, 2008 Ahmad; Nawaz (Monmouth Junction, NJ), Sun; Ying (Belle Mead, NJ), Lin; Shun Y.(Plainsboro, NJ) McNeil-PPC, Inc. (Skillman, NJ) Appl. No.: October 30...
|
|
|
Columbia Laboratories to Release Top Line Results of Phase II Lidocaine Study in Late September
- Columbia Laboratories, Inc.(Nasdaq: CBRX) today announced that its third party data management consultants have confirmed that the results from the Company's recently completed Phase II clinical trial evaluating vaginal lidocaine for...
|
